Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Matthew R. Youngman"'
Autor:
Reza Nejati, Sheryl Mitnick, James N. Gerson, John P. Plastaras, Amit Maity, Hisae Nakamura, Sarah J. Nagle, Matthew R. Youngman, Stacy Hung, Sameh Gaballa, Joanne Filicko-O'Hara, Lauren E. Strelec, Steven M. Bair, Cara M King, Terease S. Waite, Hatcher J. Ballard, Daniel J. Landsburg, Stephen J. Schuster, Elise A. Chong, Nadia Khan, Marco Ruella, Stefan K. Barta, Agata M. Bogusz, Christian Steidl, Megan S. Lim, Sunita D. Nasta, Jakub Svoboda
Publikováno v:
Haematologica
We conducted a phase I/II multicenter trial using six cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive B-cell lymphomas. Thirty-one pa
Autor:
Nirav N. Shah, Steven M. Bair, Chaitra S. Ujjani, Christina Howlett, Daniel J. Landsburg, Tatyana Feldman, Nadia Khan, Malik Faheem, Charalambos Andreadis, Stephen J. Schuster, Sunita D. Nasta, Jakub Svoboda, Matthew R. Youngman, Philippe Armand, Smith Giri, Arun N. Singavi, Nishitha Reddy, Gulrayz Ahmed, Lauren E. Strelec, Khoan Vu, Scott F. Huntington
Publikováno v:
The oncologist, vol 24, iss 7
Background Although classical Hodgkin lymphoma (cHL) is highly curable, 20%-30% of patients will not be cured with conventional treatments. The programmed death-1 (PD-1) inhibitors (PD-1i) nivolumab and pembrolizumab have been Food and Drug Administr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb8a6a1ee7764b28c5184a1848bba610
https://escholarship.org/uc/item/3q05t8vf
https://escholarship.org/uc/item/3q05t8vf
Autor:
David L. Porter, Brandon Loudon, Saar Gill, Anthony R. Mato, Stephen J. Schuster, Susan R. Rheingold, J. Joseph Melenhorst, Irina Kulikovskaya, Matthew R. Youngman, Megan M. Suhoski, Stephan A. Grupp, Simon F. Lacey, Sunita D. Nasta, Jakub Svoboda, Bruce L. Levine, Carl H. June, Daniel J. Landsburg
Publikováno v:
Blood. 132(10)
Chimeric antigen receptor (CAR)-modified T cells are being investigated in many settings, including classical Hodgkin lymphoma (cHL). The unique biology of cHL, characterized by scant Hodgkin and Reed-Sternberg (HRS) cells within an immunosuppressive
Autor:
Olga Kutovaya, James N. Gerson, Stacy Hung, Steven M. Bair, Christian Steidl, M. Reza Nejati, Lauren E. Strelec, Megan S. Lim, Daniel J. Landsburg, Elise A. Chong, Agata M. Bogusz, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Marco Ruella, Stephen J. Schuster, Matthew R. Youngman
Publikováno v:
Blood. 132:2959-2959
Background: PMBCL is a unique subtype of aggressive B-cell lymphoma representing about 5% of lymphoma cases. The diagnosis is generally based on a combination of clinical features (e.g., mediastinal mass) and pathological findings on tissue biopsy (e
Autor:
Lester Lledo, Aliza Schmidt, Simon F. Lacey, Susan R. Rheingold, Irina Kulikovskaya, Naseem Kerr, Sunita D. Nasta, Jakub Svoboda, Kim-Marie Shea, Brandon Loudon, Bruce L. Levine, Katherine T. Marcucci, Carl H. June, Anthony R. Mato, Saar Gill, David L. Porter, Amy Marshall, Stephen J. Schuster, Daniel J. Landsburg, Stephan A. Grupp, Matthew R. Youngman, J. Joseph Melenhorst
Publikováno v:
Blood. 130:653-653
Background: Cellular therapy using anti-CD19 autologous chimeric antigen receptor modified T (CART19) cells demonstrates promising outcomes in several hematologic malignancies of B-cell origin, but this therapy has not been studied in HL patients (pt